Status:
COMPLETED
Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency
Lead Sponsor:
Loyola University
Collaborating Sponsors:
Sanofi
Conditions:
Type 2 Diabetes
Renal Insufficiency
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
It is imperative to devise easy to follow, yet appropriate, guidelines for insulin use in renal-impaired patients. This will be done by comparing two regimens: 1) glargine once daily plus mealtime glu...
Detailed Description
This study will enroll 180 hospitalized patients with Type 2 diabetes and moderate to end stage renal insufficiency (estimated glomerular filtration rate is \< 30 ml/min/1.73m2 or dialysis) in the Chi...
Eligibility Criteria
Inclusion
- Type 2 Diabetes Mellitus of mor than 1year
- GFR less than 30 ml/min/1.73m2 or dialysis
- Age greater than 18years
- Entry blood glucose (fasting or random) greater than 180mg%
Exclusion
- Type 1 Diabetes Mellitus
- New onset hyperglycemia
- Pregnant
- Solid organ transplant within 1 year
- Steroids prednisone greater than 7.5mg/day or equivalent
- Hospital LOS predicted less than 2 days
- Severe liver disease
- Known hypopituitarism or adrenal insufficiency
- Patients in the ICU
- Patients with hypoglycemic unawareness
- Outpatient insulin dose less than 0.6 units/kg
Key Trial Info
Start Date :
January 21 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2011
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT00911625
Start Date
January 21 2009
End Date
June 30 2011
Last Update
April 6 2017
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern University Medical Center
Chicago, Illinois, United States, 60611
2
Rush University Medical Center
Chicago, Illinois, United States, 60612
3
Loyola University Hospital
Maywood, Illinois, United States, 60153